Do analysts rate KVAC or APLT?

Applied Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Keen Vision Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Keen Vision Acquisition 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Which has preferable valuation & earnings, KVAC or APLT?

Keen Vision Acquisition has higher earnings, but lower revenue than Applied Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Keen Vision Acquisition N/A N/A N/A N/A N/A Applied Therapeutics $1M 15.86 -$105.62M -$0.10 N/A

Is KVAC or APLT more profitable?

Keen Vision Acquisition's return on equity of 0.00% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Keen Vision Acquisition N/A N/A N/A Applied Therapeutics N/A -340.84% -175.00%

Do analysts rate XLO or APLT?

Applied Therapeutics has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Xilio Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xilio Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67

Do analysts rate APLT or INMB?

Applied Therapeutics currently has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than INmune Bio. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 INmune Bio 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50

Is APLT or INMB more profitable?

INmune Bio's return on equity of -82.87% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% INmune Bio N/A -82.87% -62.23%

Is ELTX or APLT more profitable?

Applied Therapeutics' return on equity of -340.84% beat Elicio Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Elicio Therapeutics N/A -1,266.43% -139.94% Applied Therapeutics N/A -340.84% -175.00%

Do analysts recommend APLT or EXOZ?

Applied Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Applied Therapeutics is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Applied Therapeutics 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is APLT or EXOZ more profitable?

eXoZymes' return on equity of -292.15% beat Applied Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Applied Therapeutics N/A -340.84% -175.00% eXoZymes N/A -292.15% -158.66%

Applied Therapeutics (APLT) Competitors

$0.10 0.00 (0.00%)

As of 08/28/2026

Compare

APLT vs. KVAC, XLO, INMB, ELTX, and EXOZ

Should you buy Applied Therapeutics stock or one of its competitors? Applied Therapeutics's main competitors and comparable companies include Keen Vision Acquisition (KVAC), Xilio Therapeutics (XLO), INmune Bio (INMB), Elicio Therapeutics (ELTX), and eXoZymes (EXOZ). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Applied Therapeutics compare to Keen Vision Acquisition?

Keen Vision Acquisition (NASDAQ:KVAC) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, profitability, earnings, institutional ownership, dividends and media sentiment.

Keen Vision Acquisition has a beta of -0.04, meaning that its stock price is 104% less volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

Keen Vision Acquisition's return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Keen Vision Acquisition	N/A	N/A	N/A
Applied Therapeutics	N/A	-340.84%	-175.00%

Keen Vision Acquisition has higher earnings, but lower revenue than Applied Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

51.7% of Keen Vision Acquisition shares are owned by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are owned by institutional investors. 80.2% of Keen Vision Acquisition shares are owned by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Keen Vision Acquisition's average media sentiment score of 0.00 equaled Applied Therapeutics'average media sentiment score.

Company	Overall Sentiment
Keen Vision Acquisition	Neutral
Applied Therapeutics	Neutral

Applied Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Keen Vision Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Keen Vision Acquisition	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Summary

Keen Vision Acquisition and Applied Therapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Applied Therapeutics compare to Xilio Therapeutics?

Xilio Therapeutics (NASDAQ:XLO) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

In the previous week, Xilio Therapeutics had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 2 mentions for Xilio Therapeutics and 0 mentions for Applied Therapeutics. Xilio Therapeutics' average media sentiment score of 1.82 beat Applied Therapeutics' score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Xilio Therapeutics	Very Positive
Applied Therapeutics	Neutral

Applied Therapeutics has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Applied Therapeutics is more favorable than Xilio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xilio Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Xilio Therapeutics has higher revenue and earnings than Applied Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xilio Therapeutics	$43.77M	1.35	-$35.04M	-$1.64	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

Xilio Therapeutics has a beta of -0.14, meaning that its share price is 114% less volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market.

54.3% of Xilio Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 7.5% of Xilio Therapeutics shares are held by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Applied Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -34.06%. Xilio Therapeutics' return on equity of -71.99% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xilio Therapeutics	-34.06%	-71.99%	-20.43%
Applied Therapeutics	N/A	-340.84%	-175.00%

Summary

Applied Therapeutics beats Xilio Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Applied Therapeutics compare to INmune Bio?

Applied Therapeutics (NASDAQ:APLT) and INmune Bio (NASDAQ:INMB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership and profitability.

INmune Bio's return on equity of -82.87% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
INmune Bio	N/A	-82.87%	-62.23%

INmune Bio has lower revenue, but higher earnings than Applied Therapeutics. INmune Bio is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
INmune Bio	N/A	N/A	-$45.93M	-$0.67	N/A

In the previous week, INmune Bio had 3 more articles in the media than Applied Therapeutics. MarketBeat recorded 3 mentions for INmune Bio and 0 mentions for Applied Therapeutics. INmune Bio's average media sentiment score of 1.13 beat Applied Therapeutics' score of 0.00 indicating that INmune Bio is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
INmune Bio	Positive

Applied Therapeutics currently has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' higher probable upside, analysts clearly believe Applied Therapeutics is more favorable than INmune Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
INmune Bio	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 12.7% of INmune Bio shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 21.4% of INmune Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Applied Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, INmune Bio has a beta of 0.97, suggesting that its share price is 3% less volatile than the broader market.

Summary

INmune Bio beats Applied Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Applied Therapeutics compare to Elicio Therapeutics?

Elicio Therapeutics (NASDAQ:ELTX) and Applied Therapeutics (NASDAQ:APLT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Elicio Therapeutics currently has a consensus target price of $19.75, suggesting a potential upside of 595.42%. Applied Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than Elicio Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elicio Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67

Applied Therapeutics' return on equity of -340.84% beat Elicio Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elicio Therapeutics	N/A	-1,266.43%	-139.94%
Applied Therapeutics	N/A	-340.84%	-175.00%

Elicio Therapeutics has higher earnings, but lower revenue than Applied Therapeutics. Elicio Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elicio Therapeutics	N/A	N/A	-$39.57M	-$2.17	N/A
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A

Elicio Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market.

In the previous week, Elicio Therapeutics had 4 more articles in the media than Applied Therapeutics. MarketBeat recorded 4 mentions for Elicio Therapeutics and 0 mentions for Applied Therapeutics. Elicio Therapeutics' average media sentiment score of 0.72 beat Applied Therapeutics' score of 0.00 indicating that Elicio Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Elicio Therapeutics	Positive
Applied Therapeutics	Neutral

35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 50.9% of Elicio Therapeutics shares are held by insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Elicio Therapeutics and Applied Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Applied Therapeutics compare to eXoZymes?

Applied Therapeutics (NASDAQ:APLT) and eXoZymes (NASDAQ:EXOZ) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, profitability, dividends and earnings.

eXoZymes' return on equity of -292.15% beat Applied Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Applied Therapeutics	N/A	-340.84%	-175.00%
eXoZymes	N/A	-292.15%	-158.66%

98.3% of Applied Therapeutics shares are owned by institutional investors. 1.6% of Applied Therapeutics shares are owned by insiders. Comparatively, 72.4% of eXoZymes shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, eXoZymes had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 2 mentions for eXoZymes and 0 mentions for Applied Therapeutics. eXoZymes' average media sentiment score of 0.93 beat Applied Therapeutics' score of 0.00 indicating that eXoZymes is being referred to more favorably in the news media.

Company	Overall Sentiment
Applied Therapeutics	Neutral
eXoZymes	Positive

Applied Therapeutics presently has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Applied Therapeutics is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Applied Therapeutics	1 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.67
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

eXoZymes has lower revenue, but higher earnings than Applied Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Applied Therapeutics	$1M	15.86	-$105.62M	-$0.10	N/A
eXoZymes	N/A	N/A	-$9.16M	-$1.19	N/A

Applied Therapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.93, indicating that its share price is 193% more volatile than the broader market.

Summary

eXoZymes beats Applied Therapeutics on 7 of the 13 factors compared between the two stocks.

Get Applied Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APLT vs. The Competition

Export

Metric	Applied Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$15.86M	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-1.03	11.62	273.16	25.45
Price / Sales	15.86	1,295.87	605.06	76.64
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	0.21	16.53	12.98	6.14
Net Income	-$105.62M	-$22.80M	$3.48B	$348.86M
7 Day Performance	N/A	-0.31%	0.13%	-0.80%
1 Month Performance	N/A	9.80%	7.08%	4.13%
1 Year Performance	-79.09%	55.66%	24.67%	15.17%

Applied Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APLT Applied Therapeutics	1.498 of 5 stars	$0.10 flat	$1.00 +870.9%	N/A	$15.86M	$1M	N/A	30
KVAC Keen Vision Acquisition	N/A	$11.51 flat	N/A	N/A	$63.37M	N/A	N/A	N/A
XLO Xilio Therapeutics	0.4914 of 5 stars	$9.23 -1.9%	N/A	-8.2%	$61.92M	$43.77M	N/A	70	News Coverage Positive News
INMB INmune Bio	0.7986 of 5 stars	$2.16 -3.1%	N/A	+14.8%	$61.89M	$50K	N/A	10
ELTX Elicio Therapeutics	2.7358 of 5 stars	$3.08 -1.6%	$19.75 +541.2%	-72.5%	$59.74M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APLT) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Applied Therapeutics (APLT) Competitors

APLT vs. KVAC, XLO, INMB, ELTX, and EXOZ

How does Applied Therapeutics compare to Keen Vision Acquisition?

Summary

How does Applied Therapeutics compare to Xilio Therapeutics?

Summary

How does Applied Therapeutics compare to INmune Bio?

Summary

How does Applied Therapeutics compare to Elicio Therapeutics?

Summary

How does Applied Therapeutics compare to eXoZymes?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT vs. The Competition

Applied Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Applied Therapeutics (APLT) Competitors

APLT vs. KVAC, XLO, INMB, ELTX, and EXOZ

How does Applied Therapeutics compare to Keen Vision Acquisition?

Which has more risk and volatility, KVAC or APLT?

Is KVAC or APLT more profitable?

Which has preferable valuation & earnings, KVAC or APLT?

Do insiders and institutionals hold more shares of KVAC or APLT?

Does the media prefer KVAC or APLT?

Do analysts rate KVAC or APLT?

Summary

How does Applied Therapeutics compare to Xilio Therapeutics?

Does the media prefer XLO or APLT?

Do analysts rate XLO or APLT?

Which has better valuation & earnings, XLO or APLT?

Which has more risk & volatility, XLO or APLT?

Do insiders & institutionals have more ownership in XLO or APLT?

Is XLO or APLT more profitable?

Summary

How does Applied Therapeutics compare to INmune Bio?

Is APLT or INMB more profitable?

Which has better earnings & valuation, APLT or INMB?

Does the media refer more to APLT or INMB?

Do analysts rate APLT or INMB?

Do institutionals & insiders have more ownership in APLT or INMB?

Which has more risk and volatility, APLT or INMB?

Summary

How does Applied Therapeutics compare to Elicio Therapeutics?

Do analysts recommend ELTX or APLT?

Is ELTX or APLT more profitable?

Which has preferable earnings and valuation, ELTX or APLT?

Which has more volatility & risk, ELTX or APLT?

Does the media refer more to ELTX or APLT?

Do insiders and institutionals hold more shares of ELTX or APLT?

Summary

How does Applied Therapeutics compare to eXoZymes?

Is APLT or EXOZ more profitable?

Do institutionals and insiders have more ownership in APLT or EXOZ?

Does the media favor APLT or EXOZ?

Do analysts recommend APLT or EXOZ?

Which has stronger earnings & valuation, APLT or EXOZ?

Which has more risk & volatility, APLT or EXOZ?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APLT vs. The Competition

Applied Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools